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Abstract
Background: Glioblastoma (GBM) is the most frequent and aggressive type of adult brain tumor. Most GBMs express
telomerase; a high level of intra-tumoral telomerase activity (TA) is predictive of poor prognosis. Thus, telomerase
inhibitors are promising options to treat GBM. These inhibitors increase the response to radiotherapy (RT), in vitro
as well as in vivo. Since typical treatments for GBM include RT, our objective was to evaluate the efficiency of
Imetelstat (TA inhibitor) combined with RT.
Findings: We used a murine orthotopic model of human GBM (N = 8 to11 mice per group) and μMRI imaging to
evaluate the efficacy of Imetelstat (delivered by intra-peritoneal injection) alone and combined with RT. Using a
clinically established protocol, we demonstrated that Imetelstat significantly: (i) inhibited the TA in the very center
of the tumor, (ii) reduced tumor volume as a proportion of TA inhibition, and (iii) increased the response to RT,
in terms of tumor volume regression and survival increase.
Conclusions: Imetelstat is currently evaluated in refractory brain tumors in young patients (without RT). Our results
support its clinical evaluation combined with RT to treat GBM.
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Findings
Reactivation of a telomeric maintenance mechanism is a
key and obligatory step for all cancer cells. In fact,
telomerase is reactivated in 96 % of cancer tumors. Thus,
inhibition of this enzyme is a promising option for treating
cancer [1]. GRN163L (Imetelstat) is the most advanced
telomerase inhibitor in clinical evaluation (17 completed
or ongoing clinical trials) (https://clinicaltrials.gov). In pre-
clinical assays using numerous models of solid and liquid
tumors, a reduction in tumor volume and an increase in
overall survival (OS) have been reported [2].
In addition, most cancers are treated by radiotherapy
(RT), and among the whole genome, γ-irradiation (IR)
preferentially targets telomeres [3] and induces a reduction
in telomere length [4]. Moreover, shortening telomeres [5–9]
increases cell sensitivity to IR, whereas, elongating telomeres
induces radio-resistance [5, 10]. Thus, it makes sense to
combine Imetelstat with radiotherapy, as demonstrated in
two murine models of breast cancer [6, 11].
Glioblastoma (grade IV astrocytoma)(GBM) is the most
frequent adult brain tumor, and one of the most aggressive
tumors among all human cancers. Despite a standard of
care combining surgery, radiotherapy (RT) and Temozolo-
mide chemotherapy, the median patient overall survival
(OS) still ranges from 7 to 15 months [12]. New targeted
therapies or irradiation techniques are thus urgently
needed. However, identification of cancer-specific targets
is a particular challenge in GBM as these tumors are
highly heterogeneous in terms of their histological, mo-
lecular, genetic and epigenetic features [12]. However,
most GBMs reactivate telomerase [13–15]. Among these
tumors a high intra-tumoral level of telomerase activity
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(TA) [14, 15] is predictive of poor prognosis. Two muta-
tions residing in the promoter of TERT (encoding the
catalytic subunit of the telomerase) have recently been
identified. These mutations, increasing the TA, have been
detected in many types of tumors [16], with the highest
frequency in GBM (74 % of patients). Telomerase inhibi-
tors are thus a promising option for treating GBMs.
Drug delivery into the brain is challenging as the Blood
Brain Barrier (BBB) stops most of the molecules. Hence,
the two first preclinical studies evaluating Imetelstat, in an
orthotopic location, delivered the drug directly into the
brain [17, 18]. However, in high grade glioma the BBB is
leaky [19], and a more recent publication has provided
evidence indicating that Imetelstat passes the BBB [7]. It
remains to be demonstrated that the reduction of TA is
correlated with a clinical response (such as tumor growth
reduction or OS increase). More importantly, RT is used
in all GBM treatment plans and Marian et al. have shown,
in vitro, on human GBM tumor-initiating cells that
16 weeks of pre-treatment by IMT increases cell death
and DNA damage produced by IR. However, the in vivo
efficacy of Imetelstat in combination with RT, using a real-
istic treatment plan, has never been evaluated in GBM.
In this article, we propose, using the intra-peritoneal
route in a murine orthotopic model of human GBM, to:
(i) demonstrate a reduction in tumor growth in relation
with the level of TA inhibition inside the tumor and to
(ii) evaluate if Imetelstat increases the efficiency of RT.
Considering the in vivo experiment, we chose a
glioblastoma-derived cell line with detectable TA and a
telomere length of about 4 kb (in human TA+ GBM,
telomere length ranges from 2 to 11 kb [13]). This cell
line, U87MG, is also the most suitable model for in vivo
preclinical assays [20], as it gives rise to tumors in a very
reproducible manner. All materials and methods are de-
scribed in Additional file 1.
First, we wanted to validate the efficiency of the drug
alone, before combining it with RT. The U87MG cell
line was xenografted in an orthotopic location, and mice
were treated by Imetelstat (N = 8) or by the vehicle PBS
(Phosphate Buffer Saline) (N = 8), by the intra-peritoneal
route, from day 3 (post-xenograft) to euthanasia (Fig. 1a).
Twenty-eight days post-graft, we noted a significant re-
duction in tumor volume (Fig. 1b) with the mice receiving
Imetelstat, attesting, for the first time, to the treatment’s
efficiency when using a peripheral route of injection. How-
ever, this efficiency was to be put in relation to the inhib-
ition of the TA. Thus, we measured the TA in the very
center of the tumor and observed a significant reduction
(Fig. 1c). This confirms that Imetelstat efficiently reaches
the center of the tumor. A significant and positive correl-
ation between tumor growth and the residual level of TA
was also shown (Fig. 1d). This observation proves: (i) that
the anti-tumoral activity of Imetelstat is due to its anti-
telomerase activity, and (ii) that TA plays an essential role
in GBM growth and aggressiveness, reinforcing the inter-
est in targeting telomerase to treat GBM.
We next evaluated the efficiency of the combined
treatment with RT, following a plan that would be suit-
able for human treatment. The mice were treated for
Fig. 1 Intra-peritoneal injection of Imetelstat efficiently inhibits telomerase and reduces tumor growth. a Experimental design: mice were xenografted
and intra-peritoneal injections were started three days later, either with Imetelstat (30 mg/Kg three times a week) or by an equivalent volume of PBS.
Tumor volume was determined by μMRI at day 28, and the treatment was maintained until the mice were sacrificed (when tumor growth was
predicted to be about 70 mm3 by the μMRI imaging). b Tumor volume at day 28 is significantly reduced by Imetelstat (IMT) treatment versus
PBS (Wilcoxon test). c Intra-peritoneal injection of Imetelstat is able to significantly reduce the TA inside the tumor (Wilcoxon test). d TA and
tumor volume are correlated (Spearman test), the grey and black circles correspond respectively to the mice treated by IMT or by PBS
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one month with Imetelstat and RT was delivered con-
comitantly, two weeks post induction (as validated by
our in vitro results, data not shown). The RT protocol
was a focalized IR of the brain, five times a week by 2Gy
fractions (as used for humans) for one week (Fig. 2a). On
day 26, a significant reduction in tumor volume was ob-
served by μMRI, in comparison with the PBS control group
(PBS), regardless of the treatment : Imetelstat (IMT, p =
0.0084), PBS plus RT (PBS/RT, p = 0.0053), or Imetelstat
plus RT (IMT/RT, p = 0.0004) (Figs. 2c, d). As observed in
our in vitro experiments (data not shown), we noted that
Imetelstat significantly increased the efficiency of RT, in
term of tumor volume reduction (p = 0.0414) (Figs. 2c, d).
As expected, the OS was increased in all 3 treatments
(PBS/RT, IMT or IMT/RT) (Fig. 2b left). If considering the
IMT/RT versus the PBS/RT groups we also established a
significant (p = 0.036) increase in OS (Fig. 2b right). The
median OS was respectively 30, 39, 39 and 41 days for the
Fig. 2 Imetelstat significantly increases radiotherapy efficiency in vivo. a Experimental design: mice were xenografted (D0) and intra-peritoneal injections
were started three days later (D3) either with Imetelstat (IMT, 30 mg/Kg three times a week) or by an equivalent volume of PBS, for four weeks. Two weeks
after the treatment was began (D13) mice were or were not concomitantly treated by radiotherapy (RT, 2Gy/day, five days), and imaged by μMRI at day 26
(D26). Injections were stopped at the end of the fourth week and mice were monitored until they developed debilitating disease (date used for the OS).
b Kaplan Meier representation of OS as a function of days post-xenograft, for mice treated by PBS (black solid line), Imetelstat (green solid line)
or a combination of RT with PBS (dashed black line) or with Imetelstat (dashed green line). LogRank calculated p-values are shown for all treatments
(on the left) and for IMT/RT versus PBS/RT (on the right). c Tumor volume determined by μMRI at day 26 is shown for each treatment group. p-values
were determined comparing each condition to the PBS condition, and between the PBS/RT versus the IMT/RT (p < 0.05, **p < 0.01, ***p < 0.001,
Wilcoxon test). d Display of semi-automatic GBM segmentation on T2-weighted MR images: axial plane (left), sagittal plane (middle), coronal
plane (right). A 3D reconstruction (right) showing the localization and the size of GBM (yellow) within the mouse brain (turquoise)
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PBS, IMT, RT and IMT/RT conditions. Thanks to a stand-
ard curve of tumoral growth (Additional file 2: Figure S1),
we have translated these results into tumoral volume vari-
ation: the combined treatment reduced the growth by
34 % in comparison to IMT or RT alone. Furthermore,
45 % of mice (5 over 11 mice) in the IMT/RT group have
the same or an increased OS than mice in the RT or IMT
group. To conclude, the combination of RT with Imetel-
stat significantly reduced tumor volumes and increased
the OS of the mice.
Considering the results obtained with Imetelstat alone,
we showed a significant reduction in TA, in the very
center of the tumor, and established that the residual TA
was positively correlated with the tumor’s growth. This
highlights the major role of TA in these tumors’ aggres-
siveness in agreement with previous publications setting
a correlation between patient outcome and tumoral-TA
level [14, 15]. In the future, dose optimization could be
proposed to patients, in proportion to the initial TA
level inside their tumors or their circulating tumoral
cells [21]. While, RT is an obligatory step for GBM treat-
ment, no pre-clinical data was available concerning the
combination of RT and Imetelstat for GBM treatment.
We have demonstrated a significant improvement of the
efficiency of RT, by combining it with Imetelstat for
GBM treatment, in terms of OS increase and tumor
volume reduction. It is noteworthy that we have used
RT for only one week to avoid the radical effect of intensive
RT that would have precluded any evaluation of its com-
bined effect with Imetelstat (as in Serrano et al. publication
[8]). Thus, we expect that the effect of the combination will
be even more drastic with several weeks of concomitant
RT (as commonly delivered in human GBM treatment).
Moreover, we did not observe any side effect, confirming
the results of previous preclinical assays [2].
Last, a major point of our model is that it avoids most of
the inconsistencies of previous publications, such as the
long-term cell pre-treatment before engraftment [11, 22],
or the concomitant treatment together with engraftment
[18], both of which preclude tumor engraftment and de-
velopment [23]. This anti-engraftment or anti-adhesive
[24] effect could be related to the off-target effect of Ime-
telstat on cytoskeleton destructuration [25]. Moreover, we
propose a realistic protocol for clinical use: (i) a peripheral
route of injection and not a direct intra-cerebral [18],
intra-nasal [17] or intra-tumoral [11] delivery, (ii) a
classical one-month cycle of chemotherapy and (iii) a
combined fractionated RT treatment (2Gy/fraction de-
livered locally). Overall, our data supports the useful-
ness of future clinical studies using Imetelstat combined
with RT for the treatment of GBM. The recent opening
of a clinical trial evaluating Imetelstat (alone) in refrac-
tory brain tumors in young patients comforts this con-
clusion (NCT01836549).
Additional files
Additional file 1: Materials and methods.
Additional file 2: Determination of tumor growth after U87
orthotopic xenoraft.
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